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Abstract Human papilloma virus (HPV) is the primary
etiological agent responsible for cervical cancer in women.
Although in total 16 high-risk HPV strains have been
identified so far. Currently available commercial vaccines
are designed by targeting mainly HPV16 and HPV18 viral
strains as these are the most common strains associated
with cervical cancer. Because of the high level of antigenic
specificity of HPV capsid antigens, the currently available
vaccines are not suitable to provide cross-protection from
all other high-risk HPV strains. Due to increasing reports of
cervical cancer cases from other HPV high-risk strains
other than HPV16 and 18, it is crucial to design vaccine
that generate reasonable CD8? T-cell responses for pos-
sibly all the high-risk strains. With this aim, we have
developed a computational workflow to identify conserved
cross-clade CD8? T-cell HPV vaccine candidates by
considering E1, E2, E6 and E7 proteins from all the high-
risk HPV strains. We have identified a set of 14
immunogenic conserved peptide fragments that are sup-
posed to provide protection against infection from any of
the high-risk HPV strains across globe.
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PVS Protein variability server
MHC Major histocompatibility complex
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HLA Human leukocyte antigen
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Introduction
Cervical cancer is the second most common malignant
cancer in terms of incidence and mortality rates in women
worldwide after breast cancer (Pisani et al. 1993; Collins
et al. 2006; Jemal et al. 2011; Senapathy et al. 2011; Torre
et al. 2015). Human papilloma virus (HPV) is considered
as the major etiological agent for cervical cancer which is
responsible for over 265,700 total women deaths per year
with around 527,600 new cases every year (Torre et al.
2015). It is estimated that about 80 % of women could
acquire a HPV infection in their lifetime (Baseman and
Koutsky 2005). On an average, every woman who dies
due to cervical cancer loses about 26 years of life which is
considerably greater than the average years of life lost to
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breast cancer (19.2 years) (Herzog and Wright 2007;
Pandhi and Sonthalia 2011). Till now over 200 types of
HPV strains have been sequenced (Bernard et al. 2010;
Meiring et al. 2012; McLaughlin-Drubin 2015; Supindham
et al. 2015), among them 16 are known to be high-risk
virus strains (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
68, 69, 73, and 82) (Mun˜oz et al. 2003; Markowitz et al.
2007; Sumalee et al. 2008; Meijer et al. 2009; Dames
et al. 2014) with oncogenic HPV DNAs detected in 99 %
of the cervical cancers (Dunne et al. 2007). High-risk HPV
strains are in most of the cases identified as main etio-
logical agents in cervical, anal, and other genital cancers,
among them about 70 % of cervical cancers worldwide are
only due to HPV strains 16 and 18 (Dunne et al. 2007).
For the primary prevention of cervical cancer, HPV vac-
cines are widely used as an important added tool (Ault
et al. 2004; Fife et al. 2004; Liu et al. 2012). Prophylactic
and the therapeutic formulation are the two strategies for
cervical cancer vaccine candidates. Recently, FDA
approved a vaccine named ‘Gardasil 9’ that protects
females between the ages of 9–26 against nine HPV
strains. More specifically, the first generation of Gardasil
vaccine was capable to provide protections against four
HPV strains (HPV-6, HPV-11, HPV-16, and HPV-18)
while the latest approved version of Gardasil vaccine
(Gardasil 9) provides protection against five additional
high-risk HPV strains (HPV-31, HPV-33, HPV-45, HPV-
52, and HPV-58) responsible for almost 20 % of cervical
cancers worldwide (Braaten and Laufer 2008; Petrosky
et al. 2015). Gardasil and Cervarix are prophylactic vac-
cines and offer no therapeutic benefit for persons already
infected with HPV (Wain 2010; Pandhi and Sonthalia
2011). Most of the vaccine candidates that can be used as
therapeutic vaccines include immunogenic fragments from
early proteins (targets for cellular immunity) for the res-
olution of precancerous lesions and cervical cancer (Huh
and Roden 2008). The protection offered by current vac-
cines is primarily against HPV types (16 and 18), although
cross-protection for other high-risk HPV strains cannot be
neglected. The identification of highly conserved cross-
clade epitopes suitable for therapeutic intervention is
clearly a crucial prerequisite for epitope-based vaccines
development and for diagnostic tests to distinguish infec-
tion from high or low risk HPV strains. Cytotoxic T-cell
(CTL) cross-reactivity is alleged to play an essential role
in generating immune responses (Frankild et al. 2008;
Petrova et al. 2012). HPV-specific cytotoxic CD8? T
lymphocytes immune responses can be detected in all
untreated cervical cancer patients (Eiben et al. 2002;
Valdespino et al. 2005). In animal models, cell-mediated
immunity is considered to be an important mechanism for
abolition of subclinical or neoplasic virus-infected cells,
particularly CTL which lyses tumor cells in an antigen-
specific manner (Chen et al. 1991; Feltkamp et al. 1993;
De Bruijn et al. 1998; Torres-Poveda et al. 2014). Instead
of individual epitopes, the use of the full-length protein
with a great amount of immunogenic peptides may have a
better chance to induce specific CTLs, as shown previ-
ously (Strobel et al. 2000; Adams et al. 2003; Bet et al.
2015) but the protection from all high-risk HPV strains
from single vaccination will still be a question. Selection
of immunogenic consensus conserved epitopes from the
proteins of all HPV high-risk strains may provide an
experimental basis for designing of universal HPV T-cell
vaccines. In the present work, we identified conserved
consensus immunogenic CD8? T-cell epitopes from the
proteome of all high-risk HPV strains and proposed a
peptide pool with the ability to show immunogenic
responses against all the known high-risk HPV strains.
Materials and methods
Sequence retrieval
Complete proteome of all the 16 high-risk HPV strains was
retrieved from UniProt Knowledgebase (Apweiler et al.
2004). Amino acid sequences of four HPV proteins E1, E2,
E6 and E7 were extracted from all the selected proteomes.
Subsequently, four sequence datasets were manually pre-
pared for each of the proteins from 16 high-risk HPV
strains.
Conservancy analysis
For conservancy analysis, sequence datasets were first
individually aligned using ClustalW software. The substi-
tution model was set to BLOSUM, since the mentioned
substitution matrix is based on amino acid pairs in blocks
of aligned protein segments, hence performs better in
alignments and homology searches compared to those
based on accepted mutations in closely related groups
(Henikoff and Henikoff 1992). Conservancy of the amino
acids of HPV strains among the aligned sequences of
datasets was estimated by Shannon entropy function using
protein variability server (PVS). Shannon entropy analysis
(Shannon 1948) is one of the most sensitive tools to esti-
mate the diversity of a system. For a multiple protein
sequence alignment, the Shannon entropy (H) for every
position is calculated as follows
H ¼ 
XM
i¼1
Pilog2Pi
where Pi is the fraction of residues of amino acid type i and
M is the number of amino acid types.
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Consequently, consensus sequences were created for
individual conserved fragments within Shannon entropy
threshold 2 from corresponding aligned sequence data-
sets (Gupta et al. 2012). The consensus sequences were
further used for the identification of MHC binders.
Prediction of MHC binders
The most selective step in the presentation of antigenic
peptides to T-cell receptor (TCR) is the binding of the
peptide to the MHC molecule (Yewdell and Bennink
1999). NetMHC 3.2 server was used to predict binding of
peptides to a number of different HLA alleles using arti-
ficial neural networks (ANNs) and weight matrices. Posi-
tion specific scoring matrices (PSSMs)-based SYFPEITHI
(Rammensee et al. 1999) method was employed for the
prediction of binding peptides of major histocompatibility
complex (MHC) class I. NetMHC 3.2 predicts epitopes
with length ranging from 8 to 11 amino acids. Only epi-
topes with IC50 value below 500 nM were considered as
the potential epitopes in ANNs-based prediction from the
consensus fragments for four protein datasets. As the epi-
topes were predicted from the consensus sequences of
conserved protein fragments, these epitopes were again
realigned with E1, E2, E6 and E7 proteins of all high-risk
HPV strains. Only those epitopes were kept for subsequent
analyses which were 100 % identical to their respective
proteins. Further, we performed common allele matrix
analysis (Gupta et al. 2010) to discard those epitopes whose
allelic response is coverd by more efficient epitopes from
the same high-risk HPV strain.
Prediction of non-human homologous immunogenic
peptide fragments
All the overlapping epitopes (9 mer) were merged to
design the potential immunogenic peptide fragments for
CD8? response from each of the protein datasets. A
number of immunogenic peptides may fail to raise a T-cell
response if they are recognized as self peptides due to
significant similarity exists between the antigenic peptides
and proteins of host organism. For this, the final sets of
potential immunogenic peptide fragments were checked for
their similarities with annotated human proteins using
offline BLAST similarity search.
Population coverage analysis
Population coverage analysis plays a significant role in the
epitope-based vaccine designing because of the highly
polymorphic nature of the MHC molecules (Reche and
Reinherz 2003; Stern and Wiley 1994). Population cover-
age of newly identified immunogenic peptide fragments
were individually analyzed using population coverage tool
available at IEDB web server. The tool calculates the
response of individuals set of peptide fragments with
known MHC- I restrictions on the basis of maximum HLA
binding alleles. The average projected population coverage
of class I epitopes for the populations distributed in various
human populations (ethnicities) was estimated.
Results
The E1, E2, E6 and E7 protein sequences from all high-risk
HPV strains were collected from UniProtKB and aligned
using multiple sequence alignment software clustalW. The
multiple alignment files for all the four protein data sets
with conserved regions are shown in Supplementary File 1.
The conserved fragments within aligned strains of
sequence datasets were analyzed by PVS with variability
threshold (H) B 2.0. Typically, positions with H C 2.0 are
considered variable, whereas those with H B 1 are con-
sider highly conserved (Litwin and Jores 1992). Addi-
tionally the positions with H B 2 and H[ 1 are also
considered as conserved regions (Gupta et al. 2009, 2011).
The default cutoff value (H = 1) was too strict, resulting in
fewer and smaller targets for the following analysis so the
cutoff threshold value was set as 2.0 in the present analysis
to identify reasonable conserved fragments with length C9
amino acid residues. The consensus sequences of all the
conserved regions with length C9 amino acids in four
datasets of E1, E2, E6 and E7 proteins from high-risk HPV
strains are shown in Table 1.
To generate immunological responses against any
pathogen, the binding of antigenic peptide from pathogen
and its binding affinity to MHC molecules is one of the
crucial steps (Roomp et al. 2010). Using NetMHC 3.2
server, we predicted a total of 65 unique epitopes from the
consensus sequences dataset of E1 protein. Likewise, 8
from E2, 5 from E6 and 2 unique epitopes from E7 protein
consensus sequence datasets were predicted by the server
with either strong or weak binding affinity (Supplementary
Table 1–4). As epitopes were predicted from the consensus
conserved peptide fragments of protein datasets through
NetMHC 3.2 server, there are chances that some of the
epitopes may not show 100 % identity with any of the
protein in the datasets due to presence of consensus amino
acid residues substituted during conservancy analysis. To
verify this, epitopes were realigned with the primary pro-
tein datasets of E1, E2, E6 and E7 proteins collected for
various high-risk HPV strains. Those epitopes which were
not completely mapped with any of the primary protein
sequences of high-risk HPV strains were filtered out. In this
process, 16 epitopes from E1, 2 from E2, 2 from E6 and
both the epitopes from E7 datasets were discarded. To
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predict the long immunogenic peptide fragments, all the
overlapping epitopes were merged (Table 2). In total, 15
immunogenic conserved peptide fragments were identified,
of which 11 fragments were from E1, 3 from E2 and 1
fragment was from E6 protein dataset of high-risk HPV
strains.
To further identify the minimal set of immunogenic
peptide fragment datasets to target all the high-risk HPV
strains, we discarded those peptide fragments where the
targeted HLA alleles and high-risk HPV strains were the
subsets of other highly efficient peptide fragments shown in
Table 2. In this process, immunogenic peptide sequence
ECAIFYKAR (Table 2: E2-F2) from the high-risk HPV
strain 69 was filtered out as it can be considered the subset
of immunogenic fragment E1-F6 which is also present in
type 69 HPV strain and also target the same allele besides
its affinity with other alleles. Thus, in total, we have
identified a peptide pool of 14 sequences that might be
effective to generate immunogenic responses against any
of the high-risk HPV strains. The interaction map of
immunogenic peptide fragments, their HLA allelic
responses and their presence in various HPV high-risk
strains are shown in Fig. 1. To discard peptide fragments
that can be recognized as self protein for the immune
Table 1 Conserved protein fragments from E1, E2, E6 and E7 protein datasets from all high-risk HPV strains
HPV
protein
Conserved fragment
number
Start
position
End
position
Sequence with nine or more consecutive conserved
residues filtered from protein variability server
E1 E1-1 2 12 MADPEGTDGEG
E1-2 21 31 VEAIVEKKTGD
E1-3 33 41 ISDDEDENA
E1-4 66 76 ETAQALFNAQE
E1-5 135 146 PDSGYGNTEVET
E1-6 241 257 ELVRPFKSDKTTCTDWV
E1-7 265 278 PSVAEGLKTLIKPY
E1-8 291 307 WGVIILMLIRFKCGKNR
E1-9 312 321 KLLSTLLNVP
E1-10 324 334 CMLIEPPKLRS
E1-11 336 352 AAALYWYRTGISNISEV
E1-12 362 373 RQTVLQHSFDDS
E1-13 375 388 FDLSEMVQWAFDND
E1-14 406 447 NSNAAAFLKSNCQAKYVKDCATMCRHYKRAQKRQMSMSQWIK
E1-15 455 474 DGGDWRPIVQFLRYQGVEFI
E1-16 483 516 FLKGTPKKNCIVIYGPANTGKSYFGMSLIHFLQG
E1-17 535 545 DAKIAMLDDAT
E1-18 555 572 YMRNALDGNPISIDRKHR
E1-19 574 590 LVQLKCPPLLITSNINP
E1-20 595 606 RWPYLHSRLTVF
E1-21 624 642 INDKNWKSFFSRTWSRLDL
E1-22 645 653 EEEDKENDG
E2 E2-1 7 26 METLSQRLNVCQDKILDHYE
E2-2 45 54 ECAIFYKARE
E2-3 77 89 QAIELQMALESLN
E2-4 110 118 TEPKKCFKK
E2-5 204 212 CPESVSSTS
E2-6 305 314 TTPIVHLKGD
E6 E6-1 14 23 ERPRKLHDLC
E6-2 25 33 ALETSLHDI
E6-3 76 86 FYSKISEYRHY
E6-4 113 127 CQKPLCPEEKQRHLD
E6-5 129 137 KKRFHNIAG
E7 E7-1 6 15 PTLQDIVLDL
E7-2 95 103 LQQLLMGTL
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system we performed BLAST screening of all the 14
immunogenic peptides with entire human proteome. None
of the peptide was similar to human proteome. We finally
performed the population coverage analysis of generated
immunogenic peptide pool using population coverage
analysis tool available at IEDB server (http://tools.
immuneepitope.org/tools/population). The percentage
population coverage of the immunogenic peptide pool
generated from the current analysis in various ethnicities is
shown in Table 3.
Table 2 Immunogenic peptide fragments identified from selected protein datasets of high-risk HPV strains
HPV protein fragment Immunogenic
peptide sequence
HLA alleles targeted High-risk HPV
strains mapped
Protein
name
Immunogenic
peptide
fragment
E1 E1-F1 DSGYGNTEV HLA-A6802 16, 31, 33, 58, 73
E1-F2 LVRPFKSDK HLA-A0301,HLA-A3001 33, 58
E1-F3 CMLIEPPKL HLA-A0201,HLA-A0211,HLA-A0212,HLA-
A0216,HLA-A0219,HLA-A0250
45, 59
E1-F4 ALYWYRTGISNISEV HLA-A0201,HLA-A0202,HLA-A0203,HLA-
A0206,
HLA-A0211,HLA-A0212,HLA-A0216,HLA-
A0250,HLA-A2301,HLA-A2403,HLA-A6802
16, 18, 39, 45, 68
E1-F5 DLSEMVQWAFD HLA-A0203,HLA-A0211,HLA-A0216,HLA-
A0219,HLA-A0250,HLA-B4501
18, 33, 35
E1-F6 NSNAAAFLKSNC
QAKYVKDCA
TMCRHYKRAQ
KRQMSMSQWIK
HLA-A0201, HLA-A0202,HLA-A0203,HLA-
A0206,HLA-A2402,HLA-A3201,HLA-
B1501,HLA-B1503,HLA-B2705,HLA-
A0301,HLA-A1101,HLA-A6801,HLA-
B1503,HLA-A3001,HLA-B0702,HLA-
B0801,HLA-B1517,HLA-B5801,HLA-
A3101,HLA-A3301,HLA-A2301,HLA-
A2403,HLA-A3002,HLA-A6801
39, 59, 16, 68, 45,
31, 35, 52, 69, 39,
51, 82, 18
E1-F7 WRPIVQFLRYQGVEFI HLA-B2705,HLA-B3501, HLA-B5301,HLA-
A0203,HLA-A0206,HLA-A0211,HLA-
A0216,HLA-A0250, HLA-B1503
18, 39, 45, 58, 68,
56, 59
E1-F8 PKKNCIVIYGPANT
GKSYFGMSLIHFL
HLA-A0201,HLA-A0202,HLA-A0206,HLA-
A0211,HLA-A0216,HLA-A6802,HLA-
A6901,HLA-B3901,HLA-A2301,HLA-A2402,
HLA-A2403,HLA-A2902,HLA-B1501,HLA-
A0203,HLA-A3001,HLA-A3201,HLA-
B1517,HLA-B5801,HLA-B1503,HLA-
A2603,HLA-B1502,HLA-B3501,HLA-B1503
18, 58, 31, 33, 52,
59, 45, 39
E1-F9 VQLKCPPLLITSNI HLA-B5301,HLA-A0203,HLA-A0201,HLA-
A0206,HLA-B1503,HLA-B3901,HLA-B4801
16, 31, 33, 35, 51
E1-F10 RWPYLHSRLTVF HLA-A0202,HLA-A0203,HLA-A0211,HLA-
A0250,HLA-B0801,HLA-B1501,HLA-
B1502,HLA-B1503,HLA-B1517,HLA-
B3501,HLA-B5401,HLA-A2402,HLA-A2403
31, 33, 52, 58, 68
E1-F11 KNWKSFFSRTWSRL HLA-A2301,HLA-A2403,HLA-A1101,HLA-
A3101,HLA-A3301,HLA-A6801,HLA-
B1503,HLA-A3101
16, 31, 33, 35, 52, 58
E2 E2-F1 ETLSQRLNVCQDKI HLA-A0202,HLA-A0203,HLA-A0212,HLA-
A0219,HLA-A6802,HLA-A6901
16, 31
E2-F2 ECAIFYKAR HLA-A6801 69
E2-F3 QAIELQMALESL HLA-A0202,HLA-A0211,HLA-A0219,HLA-
A0250,HLA-B4002,HLA-A0206,HLA-
A6802,HLA-A6901,HLA-B3501,HLA-B3901
39, 59, 68
E6 E6-F1 FYSKISEYRHY HLA-A2602,HLA-B1503,HLA-B1517,HLA-
A2403,HLA-A3101,HLA-A3301,HLA-A6801
16, 33, 35, 52, 58
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Discussion
In the post-genomic era, strategies of vaccine development
have progressed dramatically from traditional Pasteur’s
principles of isolating, inactivating and injecting the cau-
sative agent of an infectious disease, to reverse vaccinology
that initiates from in silico analysis of the genome infor-
mation (Akhoon et al. 2011). In silico works have attracted
considerable attention of experimental biologists for rapid
screening and identification of probable vaccine candidates
(Sakib et al. 2014; Sharma et al. 2013; Hasan et al. 2013;
Oany et al. 2014). The availability of fully sequenced
proteome from high-risk HPV strains provide an opportu-
nity for computer-aided screening of reliable peptide-based
therapeutic vaccines candidates among billions of possible
immune-active peptides.
We extracted high-risk HPV proteome for 8 HPV
specific proteins designated as E- (E1, E2, E4, E5, E6 and
E7) or L-type (L1 and L2) according to their expression in
early or late differentiation stage of the epithelium (Burd
2003; Rautava and Syrja¨nen 2012). The early secretary
proteins expressed during early differentiating stage of
epithelium development in all the 16 high-risk HPV strains.
Since the E5 protein of HPV has previously been reported
as inducer of down-regulation of MHC class I, we ignored
E5 protein in the current analysis. Moreover, E2–E5 region
has been shown to be lost when the episomal HPV DNA
integrates into host chromosome; using E2–E5 proteins as
vaccine candidates may be futile. However, since E1 and
E2 are expressed in higher levels than E6 and E7 early in
the progress of an HPV infection, it may be assumed that
these proteins may considered as good targets for vaccine
Fig. 1 Illustration of the interaction network of immunogenic peptide
fragments, High-risk HPV strains which contributed for the formation
of these fragments and MHC class I alleles are shown. Edges with
different colors represent various immunogenic peptide fragments as
shown in figure legends. High-risk HPV strains are shown in green
hexagon in the inner circle and HLA alleles on the outer circlewith red
color. From the figure it is clear that few alleles (e.g. A2602, A2603,
A2902, A3002, B0702, B1502, B4002, B4501, B4801, B5401) are
targeted by only one immunogenic peptide fragments, whilemajority of
HLA alleles (A0201, A0202, A0203, A0206, A0211, A0212, A0216,
A0219, A0250, A0301, A1101, A2301, A2402, A2403, A3001, A3101,
A3201, A3301, A6801, A6802, A6901, B0801, B1501, B1503, B1517,
B2705, B3501, B3901, B5301, B5801) are targeted by most of the
immunogenic peptides selected in this study
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designing to treat early stages of disease (Burd 2003).
Therefore, E2 protein was included for epitope-based
vaccine designing in the present study along with E1, E6
and E7 protein. Based on our computational workflow, we
generated a pool of 14 peptide fragments with length
varying from 9 to 43 amino acid residues to provide
immunogenic responses against all the high-risk HPV
strains. The hallmark of the immune system is its ability to
recognize and distinguish between self and non-self.
T-cells do this task by recognizing peptides that are bound
to MHC receptors. Epitopes are usually thought to be
derived from non-self protein antigen that interacts with
antibodies or T-cell receptors, thereby activating an
immune response. Epitopes are usually thought to be
derived from non-self protein antigen that interacts with
antibodies or T-cell receptors, thereby activating an
immune response. Also the antigen–antibody interaction is
reversible, therefore, weak interactions often lead to cross-
reactivity of antigens. The main reasons of cross-reactivity
are either the homologous proteins that are conserved
throughout the development and expressed by both the
infectious agent and the host or the viral proteins that share
short regions of amino acid sequence similarity with a non-
homologous host protein. Therefore, to exclude the epi-
topes those are conserved between the pathogen and the
host, we performed sequence alignment of the selected
pool of 14 immunogenic peptides with entire human pro-
teome. We did not observe similarity between any of the
selected immunogenic peptide fragments with human
proteome, we also discarded epitopes showing weak
interactions with HLA alleles. Thus we believe that all the
14 sequences together will form the best peptide pool to
generated immunogenic responses against any of the high-
risk HPV strains infection.
Population coverage analysis for a given set of
immunogenic peptides is important to determine their
efficacy as the frequency of expression of their targeted
HLA alleles varies across ethnicities. With the population
coverage analysis, we concluded that least immunogenic
response is shown by HPV strain 73 followed by strain 56
in almost all the ethnicities. Thus, the data indicate that
the generated peptide fragments pool will provide very
weak protection against HPV Type 73 and 56. The best
response is shown by North American population for all
the HPV high-risk strains based on the HLA alleles fre-
quency data. Overall, we proposed the pool of 14
immunogenic peptide fragments with length ranging from
9 to 43 amino acid residues to provide the protection
against all the HPV high-risk strains except Type 73 and
56 in all the ethnicities.
Conclusion
Immunoinformatics has changed the paradigm of ancient
vaccinology since it is recently emerged as a critical
field for accelerating immunology research (Baloria
et al. 2012). Moreover, the immunoinformatics
Table 3 Population coverage analysis for immunogenic peptide pooled in various ethnicities
High-risk
HPV strain
Percentage population coverage in various ethnicities
Australia
(%)
Europe
(%)
North
Africa
(%)
North
America
(%)
North-East
Asia (%)
Oceania
(%)
South
America
(%)
South-East
Asia (%)
South-West
Asia (%)
Sub-Saharan
Africa (%)
TYPE 16 81.24 94.35 63.21 95.17 69.98 88.73 53.15 86.72 79.18 85.14
TYPE 18 65.40 74.28 50.63 91.46 60.15 76.33 53.56 73.07 64.57 76.17
TYPE 31 81.33 95.31 65.99 96.89 76.13 91.12 54.37 89.97 81.73 86.83
TYPE 33 80.85 92.30 64.35 95.03 74.60 91.06 53.76 89.76 80.19 83.36
TYPE 35 81.24 94.15 62.30 95.14 69.90 88.73 52.88 86.69 78.19 82.91
TYPE 39 81.29 95.30 65.99 95.88 71.40 89.45 54.17 87.99 81.60 86.83
TYPE 45 81.29 95.30 65.99 95.88 71.40 89.45 54.17 87.99 81.60 86.83
TYPE 51 81.24 94.04 56.96 95.04 68.92 88.73 48.71 86.55 77.50 79.99
TYPE 52 81.29 95.30 65.99 95.88 74.42 89.58 54.17 88.72 81.51 86.83
TYPE 56 0.49 17.12 8.63 40.71 18.50 2.56 8.86 14.30 15.98 23.50
TYPE 58 80.85 92.75 59.07 95.17 74.34 89.51 53.56 88.50 79.96 80.90
TYPE 59 81.29 95.30 65.99 95.88 71.40 89.45 54.17 87.99 81.60 86.83
TYPE 68 81.29 95.30 65.99 95.88 73.51 89.58 54.17 88.47 81.60 86.83
TYPE 69 80.40 93.85 55.85 93.45 65.25 86.26 44.60 83.12 77.29 79.75
TYPE 73 0.00 1.58 9.82 0.92 0.00 0.00 0.00 0.03 1.63 14.68
TYPE 82 80.40 93.85 55.85 93.45 65.25 86.26 44.60 83.12 77.29 79.75
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techniques applied to T-cells have advanced to a greater
degree than those dealing with B-cells. Indeed, it is now
a common practice to identify the vaccine candidates
using in silico approaches before being subjected to
in vitro confirmatory studies (Gupta et al. 2009; Ranjbar
et al. 2015). The major objective of our study was to
identify an immunogenic peptide pool containing epi-
topes that can be effective against all the high-risk HPV
strains circulating globally. Some cross-protections were
already observed in case of previously identified vac-
cines. Such as, Cervarix vaccine which was initially
designed by targeting HPV 16 and 18 strains but later
found to provide additional cross-protections against
HPV 31, 33 and 45 strains. However, most of the high-
risk HPV strains were evolved by accumulating random
mutations in the epitopes recognizing regions and
therefore many of the high-risk strains are not effectively
targeted by available HPV vaccines. Therefore, we used
the consensus epitopes extracted from highly conserved
regions of E1, E2, E6 and E7 proteins from all the high-
risk HPV strains identified so far. The vaccine formu-
lated by the proposed peptide pool can alert the body’s
immune system to generate immunization memory cells
upon injecting. Subsequently, as these are MHC class I
epitopes, the proteasomal degradation machineries can
degrade the whole vaccine and release these conserved
epitopes in host. Furthermore, because of the conserved
nature of the epitopes the immune system will be trained
to recognize these epitopes in case of HPV infection by
any high-risk strains and thus can provide the cross-
protection. Using the computational workflow presented
in this manuscript, we identified 14 conserved
immunogenic peptide fragments from 4 early proteins
(E1, E2, E6 and E7) of 16 high-risk HPV types pro-
viding CD8? responses which can be validated experi-
mentally for the designing of an universal vaccine
against all the high-risk HPV strains.
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